ERVEBO DIN 02532603
Health Canada record
| Active ingredient(s) | RVSV [DELTA] G-ZEBOV-GP, LIVE ATTENUATED 72000000 PFU |
|---|---|
| Dosage form | Solution |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BX02 EBOLA VACCINES |
| Original market date | |
| Current status date | 09-Nov-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29418 | 2022-11-09 | New Drug Submission (NDS) |